Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

Histone deacetylase inhibitors (HDACi), including trichostatin A (TSA) and valproic acid, can alter the acetylation of histones in chromatin and enhance gene transcription. Previously we demonstrated that HDACi-treated tumor cells are capable of presenting antigen via the MHC class II pathway. In this study, we show that treatment with HDACi enhances the expression of molecules (TAP1, TAP2, LMP2, LMP7, Tapasin and MHC class I) involved in antigen processing and presentation via the MHC class I pathway in melanoma cells. HDACi treatment of B16F10 cells also enhanced cell surface expression of class I and costimulatory molecules CD40 and CD86. Enhanced transcription of these genes is associated with a significant increase in direct presentation of whole protein antigen and MHC class I-restricted peptides by TSA-treated B16F10 cells. Our data indicate that epigenetic modification can convert a tumor cell to an antigen presenting cell capable of activating IFN-γ secreting T cells via the class I pathway. These findings suggest that the abnormalities, observed in some tumors in the expression of MHC class I antigen processing and presentation molecules, may result from epigenetic repression.

[1]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[2]  T. Tomasi,et al.  Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. , 2005, International immunology.

[3]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[4]  V. Cerundolo,et al.  Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E61 , 2001, The Journal of Immunology.

[5]  R. Ricciardi,et al.  Chromatin repression by COUP-TFII and HDAC dominates activation by NF-kappaB in regulating major histocompatibility complex class I transcription in adenovirus tumorigenic cells. , 2003, Virology.

[6]  T. Tomasi,et al.  Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.

[7]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[8]  C. Slingluff,et al.  Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells* , 2006, Journal of Biological Chemistry.

[9]  S. Ferrone,et al.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications , 2005, Oncogene.

[10]  Y. Belkaid,et al.  Antigen Requirements for Efficient Priming of CD8+ T Cells by Leishmania major-Infected Dendritic Cells , 2005, Infection and Immunity.

[11]  J. Ting,et al.  Class II Enhanceosome Formation and Major Histocompatibility Complex Gamma Interferon-Induced CIITA Function Histone Deacetylase 1 / mSin 3 A Disrupts , 2003 .

[12]  T. Tomasi,et al.  An epigenetically altered tumor cell vaccine , 2004, Cancer Immunology, Immunotherapy.

[13]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[14]  Michael Bitzer,et al.  Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. , 2005, Cancer research.

[15]  Hui Li,et al.  HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. , 2006, Biochemical and biophysical research communications.

[16]  P. Slootweg,et al.  Mutation in the β2m gene is not a frequent event in head and neck squamous cell carcinomas , 1999 .

[17]  Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. , 2000 .

[18]  Mark A. Brown,et al.  Epigenetic aberrations and cancer , 2006, Molecular Cancer.

[19]  E. Bagiella,et al.  Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. , 2004, Cellular immunology.

[20]  R. Offringa,et al.  Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. , 1998, Cancer research.

[21]  Y. Komatsu,et al.  Histone deacetylase inhibitors up-regulate the expression of cell surface MHC class-I molecules in B16/BL6 cells. , 1998, The Journal of antibiotics.

[22]  Wen‐Ming Yang,et al.  Histone Deacetylase Activity Represses Gamma Interferon-Inducible HLA-DR Gene Expression following the Establishment of a DNase I-Hypersensitive Chromatin Conformation , 2001, Molecular and Cellular Biology.

[23]  P M Kloetzel,et al.  Peptide antigen production by the proteasome: complexity provides efficiency. , 1996, Immunology today.

[24]  F. Garrido,et al.  Coordinated downregulation of the antigen presentation machinery and HLA class I/β2‐microglobulin complex is responsible for HLA‐ABC loss in bladder cancer , 2005, International journal of cancer.

[25]  B. Seliger,et al.  Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. , 2005, Cancer research.

[26]  Robert Tampé,et al.  Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts , 1998, European journal of immunology.

[27]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[28]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[29]  A. Concha,et al.  Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression , 2000, Cancer Immunology, Immunotherapy.

[30]  P. A. Peterson,et al.  Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells , 1999, The EMBO journal.

[31]  B. Seliger,et al.  Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. , 2000, Tissue antigens.

[32]  S. Ferrone,et al.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. , 2006, Cancer research.

[33]  H. Karahashi,et al.  Endothelial Cells and Murine Macrophages TLR 2-Mediated Signaling in Human Differentially Modulates TLR 4-and Mastoparan , a G Protein Agonist Peptide , 2005 .

[34]  P. Marks,et al.  Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.

[35]  T. Tsuruo,et al.  Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. , 2001, Cancer research.

[36]  T. Tomasi,et al.  Epigenetic regulation of immune escape genes in cancer , 2006, Cancer Immunology, Immunotherapy.

[37]  A. Dueñas-González,et al.  Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid , 2006, Journal of Translational Medicine.

[38]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[39]  S. Ferrone,et al.  Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells , 2006, Oncogene.

[40]  B. Seliger,et al.  Characterization of the Major Histocompatibility Complex Class I Deficiencies in B 16 Melanoma Cells 1 , 2001 .

[41]  M. Maio,et al.  Methylation‐regulated expression of HLA class I antigens in melanoma , 2003, International journal of cancer.

[42]  M. Szyf,et al.  Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. , 2007, Biochemical pharmacology.